Emerald Health Pharmaceuticals is developing drug product candidates derived from cannabinoids for the treatment of central nervous system, autoimmune, and other diseases. The Company has two families of new chemical entities, derived from synthetic CBD and CBG, that it has modified through rational drug design to affect validated receptors and pathways in the body pertinent to targeted diseases. Its first drug candidate, EHP-101, has completed preclinical proof-of-concept and a Phase I human study and is being developed for the treatment of multiple sclerosis and systemic sclerosis. Its second product candidate, EHP-102, is in preclinical development and is focused on treating Huntington’s disease and Parkinson’s disease.
DATA PRESENTATION /